In the present study, we evaluated the effects of combination therapy with niceritrol and pravastatin in patients with hyperlipidaemia. A total of 62 patients with hyperlipidaemia, defined as total cholesterol levels above 220 mg/dl or triglyceride levels above 150 mg/dl, were recruited. Patients were divided into two groups: Group N received initial therapy with niceritrol 750 -1500 mg/day, and those in Group P, pravastatin 10 mg/day. After 8 weeks, pravastatin 10 mg/day was added to the Group N treatment regimen for a further 8 weeks, while patients in Group P were given niceritrol 750 -1500 mg/day in addition to pravastatin for 8 weeks. After the 8-week combination therapy study period, total cholesterol levels were 209.6 mg/dl in Group N and 220.7 mg/dl in Group P. Decreased triglyceride and lipoprotein(a) levels and increased high-density lipoprotein cholesterol levels, neither of which were achieved by pravastatin administration alone, were achieved with the combination of pravastatin and niceritrol. We conclude that when a single lipidlowering drug fails to show therapeutic value, attempting combination therapy with a nicotinic acid preparation and a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is worthwhile.
Introduction
It has been suggested that lifestyle changes, such as a more westernized diet, have led to an increased incidence of hyperlipidaemia in Japan. In addition, many studies have reported that hyperlipidaemia is the most important risk factor for coronary heart disease (CHD). 1, 2 Moreover, the results of primary prevention studies evaluating the prevention of the initial onset of CHD, and those of secondary prevention studies evaluating the prevention of further progression or relapse of primary CHD, have shown that the development of CHD can be prevented by reducing blood cholesterol levels. 3 -9 In the USA, the National Cholesterol Education Program Adult Treatment Panel II (NCEP-ATP II) 10 has recommended nicotinic acid preparations, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and bile acid-binding resins as the first-choice treatment options for hypercholesterolaemia. If administration of any of these agents fails to decrease cholesterol levels sufficiently, however, combination therapy using several different agents has been shown to be effective. 11 Therefore, further attention is likely to be focused on combination therapy because of the increasing number of patients with hyperlipidaemia.
In the present study, we evaluated the effects of combination therapy with niceritrol, a nicotinic acid preparation, and pravastatin, an HMG-CoA reductase inhibitor.
Patients and methods PATIENTS
A total of 62 hyperlipidaemic patients with total cholesterol levels above 220 mg/dl or triglyceride levels above 150 mg/dl were recruited to this study. Patients with nephropathy or those considered inappropriate for inclusion by their attending physicians were excluded from the study. Informed consent was obtained from all patients prior to their participation in the study.
METHODS
Patients were randomized to receive initial monotherapy with either niceritrol (Group N) or pravastatin (Group P). In Group N, patients received niceritrol 750 -1500 mg/day (divided into three daily doses) for 8 weeks, then a single dose of pravastatin 10 mg/day was added for a further 8 weeks. In Group P, a single dose of pravastatin 10 mg/day was administered for 8 weeks, then niceritrol 750 -1500 mg/day (divided into three daily doses) was added for a further 8 weeks ( Fig. 1 ). Combination therapy was not given to patients whose total cholesterol levels had fallen below 200 mg/dl after the 8-week monotherapy period.
Fasting blood samples were collected from both groups before drug administration was initiated, and again after 8 and 16 weeks of treatment to evaluate the effects of the medication on serum lipid levels. The following were evaluated: total cholesterol; triglyceride; high-density lipoprotein cholesterol (HDL-C); lipoprotein(a) (Lp[a]); HDL-2; HDL-3; apolipoprotein (Apo)A- 12 CETP levels were measured using a synthetic substrate. 13 Paired Student's t-tests were used to analyse the data.
Results

PATIENT CHARACTERISTICS
Group N consisted of 28 patients and Group P, 34 patients. One patient in Group N did not receive combination therapy with pravastatin because his total cholesterol levels fell below 200 mg/dl after the 8-week administration of niceritrol, and was excluded from the analysis. A further seven patients in Group N and nine in Group P were excluded as adverse reactions led to treatment being discontinued. In addition, three patients in Group P withdrew from the study, and a patient from each group failed to meet the inclusion criteria. Data from 19 patients in Group N and 21 patients in Group P were included for final analysis in this study. There was no significant difference in baseline patient characteristics between the two groups ( Table 1 ).
EFFECTS OF COMBINATION THERAPY ON TOTAL CHOLESTEROL LEVELS
Following 8 weeks of monotherapy, total cholesterol levels fell by 7.5% in Group N and by 10.6% in Group P. After 8 more weeks of combination therapy, total cholesterol levels fell further by a mean of 14.3% in Group N and by 12.0% in Group P. Overall, compared with baseline, total cholesterol levels fell by a mean of 20.3% in Group N and 21.4% in Group P after combination therapy. Of the 40 patients who completed the course of initial monotherapy, total cholesterol levels below 220 mg/dl were maintained in 12 patients (five in Group N and seven in Group P). In addition, total cholesterol levels below 220 mg/dl were maintained in 26 patients (12 in Group N and 14 in Group P) who received combination therapy ( 
EFFECTS OF COMBINATION THERAPY ON LDL-C LEVELS
After 8 weeks of monotherapy, LDL-C fell by 9.9% in Group N and by 13.6% in Group P. After combination therapy, LDL-C levels fell further by a mean of 18.6% in Group N and 16.6% in Group P. Compared with baseline, LDL-C levels fell by a mean of 25.9% in Group N and 28.2% in Group P. Of the 40 patients who received initial monotherapy, LDL-C levels below 140 mg/dl were maintained in 12 patients (five in Group N and seven in Group P). Furthermore, LDL-C levels below 140 mg/dl were maintained in 24 patients (nine in Group N and 15 in Group P) who completed the course of combination therapy.
EFFECTS OF COMBINATION THERAPY ON TRIGLYCERIDE LEVELS
After 8 weeks of monotherapy, triglyceride levels decreased by 17.1% in Group N and increased by 0.3% in Group P. After combination therapy, the levels fell by a mean of 9.5% in Group N and 33.6% in Group P. Compared with baseline, triglyceride levels decreased by a mean of 34.3% in Group N and 35.1% in Group P overall. 
EFFECTS OF COMBINATION THERAPY ON HDL-C LEVELS
After monotherapy, percentage changes in HDL-C levels were +14.9% in Group N and -2.6% in Group P. After combination therapy, HDL-C levels increased by a mean of 1.3% in Group N and 14.3% in Group P. Compared with baseline, HDL-C levels Changes in lipid profiles following combination therapy for hyperlipidaemia
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GENERAL CLINICAL LABORATORY EXAMINATIONS
After combination therapy, HbA 1c levels increased significantly (P < 0.05) in Group N; and in Group P, red blood cell counts (P < 0.05), FBS (P < 0.01) and HbA 1c (P < 0.05) levels increased significantly. In addition, creatinine levels were significantly higher (P < 0.01) in Group P than in Group N both at the beginning and at the completion of combination therapy (Table 3 ).
ADVERSE REACTIONS
Adverse reactions were observed in seven Group N patients and nine Group P patients. Of these, five Group N patients complained of adverse reactions such as rashes, flushing, or poor appetite during the administration of niceritrol alone. The two other patients in Group N reported adverse reactions such as nausea and itching during the pravastatin co-administration period. Drug administration was discontinued in these seven patients. In Group P, drowsiness and gastric discomfort were noted in two patients during initial monotherapy, and the other seven patients reported flushing and itching during the niceritrol co-administration period. Drug administration was also discontinued in these nine Group P patients.
TABLE 3: Changes in clinical laboratory tests following combination therapy for hyperlipidaemia
Group N a AST, aspartate transaminase; ALT, alanine transaminase; BUN, blood urea nitrogen; TGF-β, transforming growth factor-β.
Discussion
Coronary heart disease is frequently associated with the rupture of intra-coronary plaques, which may be formed by foam cells with accumulated cholesterol. 14 It has been suggested that excess LDL in plasma becomes oxidized and accumulates in macrophages, which convert into foam cells.
The results of the Framingham study 1 suggested that raised serum total cholesterol levels increase the incidence of CHD. In addition, the Multiple Risk Factor Intervention Trial Research Group 2 followed 316 099 male subjects over 12 years and reported that raised blood pressure, raised cholesterol and smoking were independent risk factors that significantly increase the incidence of CHD. These findings suggest that improvement of various risk factors, in particular hyperlipidaemia, is important to prevent the development of CHD. Many clinical studies have reported that CHD could be prevented by improving serum lipid levels. 3 -9 Based on the results of these studies, the NCEP established a target total cholesterol level of 200 mg/dl and below for the initial prevention of CHD, and another target total cholesterol level of 180 mg/dl and below for the secondary prevention of CHD. 10 In 1997, the Japan Arteriosclerosis Society established guidelines for the treatment of hyperlipidaemia, with a post-treatment target total cholesterol level of below 220 mg/dl in patients with no other risk factors for arteriosclerosis. 15 The development of HMG-CoA reductase inhibitors (statins) as lipid-lowering drugs facilitated the effective treatment of hypercholesterolaemia, and successful results have been reported in CHD prevention studies using these agents. 9,16 -18 Nicotinic acid decreases total cholesterol and triglyceride levels in addition to increasing HDL-C levels. 19 CHD prevention studies have also confirmed the benefits of treatment with nicotinic acid. 3 -5 Furthermore, it has been reported that nicotinic acid markedly improves coronary stenosis 8, 20 and electrocardiographic ST segment. 21 Administration of nicotinic acid has also been shown to reduce serum Lp(a) levels. 22, 23 Because of its high homology with plasminogen, Apo(A), an apoprotein in Lp(a), is thought to be a lipoprotein that might link serum lipids with the coagulationfibrinolysis system. Rosengren et al. 24 followed 135 male subjects aged between 50 years and 59 years with no history of CHD in the previous 6 years, and reported no significant differences in total cholesterol, triglyceride and blood pressure levels between patients in whom CHD developed and those in whom it did not. They also noted, however, that Lp(a) levels were significantly higher in patients with CHD. In addition, several studies have previously reported that Lp(a) may be an independent risk factor for arteriosclerotic diseases. 25 -27 The Lp(a)decreasing action of nicotinic acid may therefore contribute to its anti-arteriosclerotic action.
In the present study of 62 patients with hyperlipidaemia, we evaluated the effects of combination therapy with niceritrol and pravastatin, an HMG-CoA reductase inhibitor, with the expectation of a further decrease in cholesterol levels and improvement in triglyceride, HDL-C and Lp(a) levels. As reported by Pasternak et al., 11 total cholesterol and LDL-C levels after combination therapy were markedly lower than those after the administration of a single lipid-lowering agent. In the present study, the target total cholesterol level (220 mg/dl) was almost achieved using the combination therapy regimen, as was the target LDL-C level (140 mg/dl). It was also ©2002 Cambridge Medical Publications confirmed that decreased triglyceride and Lp(a) levels and increased HDL-C levels, which were not achieved by administration of pravastatin alone, were achieved after combination therapy with pravastatin and niceritrol. Moreover, the serum lipid profiles did not markedly change after combination therapy regardless of the type of initial lipidlowering agent.
These findings suggest that the combination of niceritrol and pravastatin synergistically enhances the characteristics of the respective drugs, thus markedly improving serum lipid levels. Combination therapy with niceritrol and pravastatin may therefore be useful in the prevention of arteriosclerosis. Changes in the severity of adverse reactions can be problematic in combination therapy. In this study, however, neither severe adverse reactions nor clinically significant abnormal laboratory findings were observed. As only one of 62 patients showed total cholesterol levels below 200 mg/dl while receiving monotherapy, combination therapy may be necessary to decrease cholesterol levels sufficiently in hyperlipidaemia.
We conclude that when single-drug therapy for hyperlipidaemia fails to show sufficient therapeutic value, it is worthwhile attempting combination therapy with a nicotinic acid preparation and an HMG-CoA reductase inhibitor because of the efficacy and safety of this combination.
